Health ❯ Healthcare ❯ Oncology

Clinical Trials

Phase 2 Trials Phase 3 Trials Patient Outcomes Adverse Effects Drug Development Metastatic Colorectal Cancer Non-Small Cell Lung Cancer NRG-LU005 Study Non-Muscle-Invasive Bladder Cancer Patient Response

Merck and Other Drugmakers Weigh Bids for Inhibrx’s Keytruda-Linked Cancer Drug

The interest highlights demand for add-on therapies that could bolster Keytruda before key patents expire in 2028.

IDEAYA Combo Doubles Progression-Free Survival in Uveal Melanoma Trial

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

Epcoritamab Improves PFS but Not OS in Phase 3 DLBCL Trial

Pooled Data Tie Early AE Management to Greater Zolbetuximab Benefit in Gastric/GEJ Cancer

Mount Sinai Deploys PRISM AI to Match Cancer Patients to Trials Systemwide

Zymeworks and BeOne Say Phase 3 Zanidatamab Regimens Top Two Years’ Survival in First-Line HER2+ GEA

Silevertinib Delivers 60% Response and Strong CNS Activity in First-Line NSCLC With Non-Classical EGFR Mutations

mRNA Covid Vaccination Linked to Longer Survival When Given Near Cancer Immunotherapy, Nature Study Finds

mRNA COVID Vaccination Linked to Longer Survival With Cancer Immunotherapy, Data Presented at ESMO

ASCENT-03 Finds Sacituzumab Govitecan Extends PFS Over Chemotherapy in First-Line PD-L1–Negative TNBC

Padcev–Keytruda Cuts Recurrence and Death Risk in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

FDA Approves Lilly’s Inluriyo for ESR1‑Mutated Advanced Breast Cancer

King’s Spin-out Targets Human Trials for Oral Cancer Drug After Promising Mouse Results

New BTC Cell Line Atlas Unveils Molecular Subtypes and Therapeutic Targets

FDA Approves Adaptimmune's Groundbreaking T-Cell Therapy for Rare Cancer